Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stereotactic radiosurgery yields higher overall survival in patients with RCC metastatic to the brain

Haque W et al. Clinical Genitourinary Cancer 3 April 2018

Key clinical point: Treatment with stereotactic radiosurgery was superior to non-stereotactic radiotherapy for overall survival in patients with renal cell carcinoma metastatic to the brain.

Major finding: Higher overall survival was observed in the stereotactic radiosurgery cohort both before and following propensity matching. On subset analysis, differences persisted when stratifying for nephrectomy (p<0.001 for all). Treatment at an academic center independently predicted a higher rate of overall survival.

Study details: Data for 2005-2014 in the National Cancer Data Base for metastatic RCC and delivery of intracranial radiotherapy found 2,312 patients, 813 (35%) of whom received SRS and 1,499 of whom received non-SRS radiotherapy. Use of SRS increased from 27% in 2005 to 44% in 2014, and was less often given to low income and uninsured/Medicaid patients (p<0.05).

Disclosures: The researchers had no relevant financial disclosures.

Source: Haque W et al. Clinical Genitourinary Cancer 3 April 2018


Haque W et al. Clinical Genitourinary Cancer 3 April 2018

This Week's Must Reads

Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018

Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142

Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits

The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32

Must Reads in Renal Cell Carcinoma

Obesity tied to higher risk of clear cell RCC, Callahan CL et al. Cancer Epidemiol. 2018 Jul 18. doi: 10.1016/j.canep.2018.07.002

Partial nephrectomy for localized RCC, Cahn D et al. AUA Annual Meeting, Abstract PD07-04

RFA for small renal tumors holds up over long term, Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

Pazopanib active in von Hippel-Lindau disease neoplasms, Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X

Improved RCC survival attributed to better therapy, not earlier diagnosis, Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023